The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BLCO | -23.09% | N/A | N/A | -22% |
| S&P | +16.9% | +95.99% | +14.39% | +65% |
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.28B | 5.1% |
| Gross Profit | $686.00M | 4.1% |
| Gross Margin | 53.68% | -0.5% |
| Market Cap | $4.60B | -9.8% |
| Market Cap / Employee | $0.34M | 0.0% |
| Employees | 13.5K | 1.5% |
| Net Income | -$58.00M | 60.8% |
| EBITDA | $118.00M | -21.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $272.00M | -9.9% |
| Accounts Receivable | $1.08B | 9.9% |
| Inventory | 1.1K | -1.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.93B | 7.1% |
| Short Term Debt | $28.00M | -6.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.02% | 1.7% |
| Return On Invested Capital | -0.65% | -1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$57.45M | -1.8% |
| Operating Free Cash Flow | $35.18M | 140.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.04 | 0.96 | 0.79 | 0.72 | -5.68% |
| Price to Sales | 1.46 | 1.33 | 1.06 | 0.94 | -17.21% |
| Price to Tangible Book Value | -4.61 | -4.62 | -3.30 | -2.82 | -22.59% |
| Enterprise Value to EBITDA | 63.87 | 50.68 | 217.81 | 79.29 | 25.01% |
| Return on Equity | -5.5% | -4.8% | -5.6% | -4.2% | -37.74% |
| Total Debt | $4.63B | $4.94B | $4.83B | $4.96B | 7.06% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
